Johnson & Johnson (JNJ)
Summary
JNJ Chart
People also search for
Why Procter & Gamble's Quieter Dividend Outpaces Johnson & Johnson's Growth Story
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.
These 3 Dividend Stocks Have Survived Every Recession Since 1970. Retirees Trust Them for a Reason.
Retirees rarely want excitement from an income holding. They want a check that arrives, gets bigger, and does not care what the economy is doing.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KH Kevin Heal ARGUS INVESTORS' COUNSEL Inc. | 3,120 | $595,834.23 | $788,221.2 | $192,386.97 | 32.29% |
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 70,522 | $12.17M | $17.82M | $5.64M | 46.37% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 13,582 | $2.26M | $3.48M | $1.22M | 54.03% |
 Michelle S. Hickox FIRST FINANCIAL BANKSHARES Inc. | 638,883 | $101.78M | $167.27M | $65.49M | 64.35% |
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 18,428 | $3.13M | $4.72M | $1.59M | 50.7% |
Johnson & Johnson Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JB Jayson Bedford Raymond James | 546.69 | $136,656.66 | $145,819.22 | $9,162.56 | 6.7% |
| MN Michael Nedelcovych TD Cowen | 414.42 | $100,000 | $110,538.75 | $10,538.75 | 10.54% |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Media Industry | Communication Services Sector | Joaquin Duato CEO | NYSE Exchange | 478160104 CUSIP |
| US Country | 141,700 Employees | 25 Aug 2026 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
